Supplement 2: STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used	In the title and abstract
		term in the title or the abstract	(pages 1 and 2)
		(<i>b</i>) Provide in the abstract an informative and balanced	Page 2
		summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	Page 4
		investigation being reported	
Objectives	3	State specific objectives, including any prespecified	Page 6
		hypotheses	
Methods		••	
Study design	4	Present key elements of study design early in the paper	Page 6
Setting	5	Describe the setting, locations, and relevant dates,	Pages 6 and 7
		including periods of recruitment, exposure, follow-up,	
		and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and	Pages 7 and 8
-		methods of selection of participants	
Variables	7	Clearly define all outcomes, exposures, predictors,	Pages 7 and 8
		potential confounders, and effect modifiers. Give	
		diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and	Pages 7 to 9
measurement		details of methods of assessment (measurement).	-
		Describe comparability of assessment methods if there	
		is more than one group	
Bias	9	Describe any efforts to address potential sources of	Pages 8 and 9
		bias	
Study size	10	Explain how the study size was arrived at	Not applied
Quantitative variables	11	Explain how quantitative variables were handled in the	Pages 8 and 9
		analyses. If applicable, describe which groupings were	
		chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those	Pages 8 and 9
		used to control for confounding	
		(b) Describe any methods used to examine subgroups	Not applied
		and interactions	
		(c) Explain how missing data were addressed	Pages 7 and 8
		(d) If applicable, describe analytical methods taking	Not applied
		account of sampling strategy	
		(<u>e</u>) Describe any sensitivity analyses	Pages 8 and 9 (validation
			models)
Results			
Participants	13*	(a) Report numbers of individuals at each stage of	Figure 2, page 8 and
		study—eg numbers potentially eligible, examined for	Table 1, pages 9 to 11

		eligibility, confirmed eligible, included in the study,	
		completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	Not applied
		(c) Consider use of a flow diagram	Figure 2, page 7
Descriptive data	14*	(a) Give characteristics of study participants (eg	Table 1, pages 9 to 11
		demographic, clinical, social) and information on	
		exposures and potential confounders	
		(b) Indicate number of participants with missing data	Table 1, pages 9 to 11
		for each variable of interest	
Outcome data	15*	Report numbers of outcome events or summary	Table 1, pages 9 to 11
		measures	
Main results	16	(a) Give unadjusted estimates and, if applicable,	Table 1, pages 9 to 11
		confounder-adjusted estimates and their precision (eg,	(unadjusted) and Tables 2
		95% confidence interval). Make clear which	and 3, pages 12 and 13
		confounders were adjusted for and why they were	(adjusted).
		included	
		(b) Report category boundaries when continuous	Not applied.
		variables were categorized	
		(c) If relevant, consider translating estimates of	Not applied.
		relative risk into absolute risk for a meaningful time	
		period	
Other analyses	17	Report other analyses done-eg analyses of subgroups	Pages 14 and 15,
		and interactions, and sensitivity analyses	predictive model for
			death from COVID-19
Discussion			
Key results	18	Summarise key results with reference to study	Pages 15 and 16
		objectives	
Limitations	19	Discuss limitations of the study, taking into account	Page 16
		sources of potential bias or imprecision. Discuss both	
		direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results	Pages 16 to 18
		considering objectives, limitations, multiplicity of	
		analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the	Page 19
		study results	
Other information			
Funding	22	Give the source of funding and the role of the funders	Not applied.
		-	
		for the present study and, if applicable, for the original	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.